(b)
| Normal or mild | Advanced CAV | Microarray versus PCR (N = 43) | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Variable | Microarray (N = 7) | RT-PCR (N = 28) | P-value | Microarray (N = 3) | RT-PCR (N = 5) | P-value | Microarray (N = 10) | RT-PCR (N = 33) | P-value |
| Time after HTx (days) | 232 (81–298) | 81 (7–171) | .002 | 42 (41–96) | 55 (41–167) | .571 | 154.5 ± 99.5 | 76.4 ± 47.5 | .037 |
| Follow-up time (years) | 5.3 (4.8–5.8) | 5.5 (4.6–6.2) | .433 | 5.6 (5.4–5.7) | 5.7 (5.1–5.8) | .451 | 5.3 ± 0.3 | 5.4 ± 0.4 | .583 |
| Male gender recipient | 6 (85.7%) | 21 (75%) | 1 | 3 (100%) | 4 (80%) | 1 | 9 (90%) | 25 (75.8%) | .659 |
| Male gender donor | 6 (85.7%) | 20 (21.4%) | .648 | 2 (66.7%) | 3 (60%) | 1 | 8 (80%) | 23 (69.7%) | .698 |
| Caucasian recipient | 5 (71.4%) | 21 (75%) | .781 | 3 (100%) | 5 (100%) | 8 (80%) | 26 (78.8%) | .823 | |
| Caucasian donor | 7 (100%) | 17 (60.7) | .26 | 1 (33.3%) | 2 (40%) | .641 | 8 (80%) | 19 (57.6%) | .433 |
| Recipient age | 55.6 ± 8.2 | 52.6 ± 10.5 | .43 | 48.6 ± 13.5 | 61.4 ± 8.0 | .393 | 53.5 ± 9.8 | 53.9 ± 10.5 | .916 |
| Donor age | 31.7 ± 11.6 | 32.8 ± 13.0 | .888 | 44.1 ± 7.9 | 41.55 ± 13.6 | 1 | 35.4 ± 11.8 | 34.1 ± 13.3 | .559 |
| ICM recipient | 5 (71.4%) | 14 (50%) | .941 | 1 (33.3%) | 4 (80%) | .293 | 6 (60%) | 18 (54.5%) | .668 |
| LVAD | 3 (42.9%) | 7 (25%) | .31 | 2 (66.7%) | 2 (40%) | 1 | 5 (50%) | 9 (27.3%) | .252 |
| Recipient CMV (+) | 2 (28.6%) | 11 (39.3%) | .523 | 0 (0.0%) | 2 (40%) | .449 | 2 (20%) | 13 (39.4%) | .291 |
| Donor CMV (+) | 3 (42.9%) | 14 (50%) | .822 | 2 (66.7%) | 4 (80%) | 1 | 5 (50%) | 18 (54.5%) | .904 |
| Ischemic times (Min) | 188.75 ± 65.13 | 183.9 ± 49.2 | .706 | 138.0 ± 36.6 | 156.0 ± 7 | .786 | 167 ± 57.5 | 178.7 ± 45.6 | .495 |
| Daclizumab induction | 7 (100%) | 24 (85.7%) | .562 | 3 (100%) | 4 (80%) | 10 (100%) | 28 (84.8%) | .32 | |
| Prednisone | 7 (100%) | 28 (100%) | — | 3 (100%) | 5 (100%) | 10 (100%) | 33 (100%) | ||
| Prednisone dose | 8.7 ± 7.8 | 16.3 ± 10.2 | .015 | 13.3 ± 2.9 | 13.0 ± 4.5 | .845 | 10.1 ± 6.8 | 15.79 ± 9.5 | .041 |
| Maintenance regimen | .85 | .4 | .727 | ||||||
| Cyclosporine | 6 (85.7%) | 24 (85.7%) | 3 (100%) | 4 (80%) | 9 (90%) | 28 (84.8%) | |||
| Tacrolimus | 1 (14.3%) | 3 (10.7%) | 0 (0.0%) | 0 (0.0%) | 1 (10%) | 3 (9.1%) | |||
| Sirolimus | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 1 (20%) | 0 (0.0%) | 2 (6.1%) | |||
| Cyclosporine levels (ng/ml) | 437.0 ± 489.4 | 312.5 ± 226 | .686 | 225.3 ± 26.6 | 229.25 ± 22.6 | 1 | 357.6 ± 386 | 300.6 ± 211 | .47 |
| Tacrolimus levels (ng/ml) | 8.5 ± 0.2 | 11.7 ± 2.5 | .083 | — | — | 8.5 ± 0.2 | 11.7 ± 2.5 | .083 | |
| Sirolimus levels (ng/ml) | — | 6 | — | 5.6 | — | 11.7 ± 2.5 | — | ||
| Mycophenolate | 6 (85.7%) | 24 (85.7%) | 1 | 3 (100%) | 5 (100%) | 9 (90%) | 28 (84.8%) | 1 | |
| Azathioprine | 0 (0.0%) | 0 (0.0%) | — | 0 (0.0%) | 0 (0.0%) | — | 0 (0.0%) | 0 (0.0%) | — |
| Simvastatin | 1 (14%) | 2 (7%) | .499 | 1 (33%) | 0 (0%) | .375 | 2 (20%) | 2 (6%) | .226 |
| Cellular rejection (ISHLT) | .123 | .315 | .127 | ||||||
| 0R | 4 (57.1%) | 24 (85.7%) | 2 (66.7%) | 4 (80%) | 6 (60%) | 28 (84.8%) | |||
| 1R | 3 (42.9%) | 4 (14.3%) | 0 (0.0%) | 1 (20%) | 3 (30%) | 5 (15.1%) | |||
| 2R | 0 (0.0%) | 0 (0.0%) | 1 (33.3%) | 0 (0.0%) | 1 (10%) | 0 (0.0%) | |||
| New Episodes of Rejection | |||||||||
| 1R/1B | 0 (0–1) | 0 (0–4) | .3 | 0 (0–0) | 0 (0–3) | .439 | 0 (0–1) | 0 (0–4) | .17 |
| 2R | 1 (0–1) | 0 (0–2) | .59 | 1 (0–1) | 0 (0–1) | .217 | 1 (0–1) | 0 (0–2) | .32 |
| 2R/3A | 0 (0–1) | 0 (0–2) | .4 | 0 (0–0) | 0 (0–3) | .439 | 0 (0–1) | 0 (0–3) | .235 |
HTx: heart transplant; LVAD: left ventricular assist device; RT-PCR: real time polymerase chain reaction.